CN1674893A - 苯并咪唑衍生物 - Google Patents

苯并咪唑衍生物 Download PDF

Info

Publication number
CN1674893A
CN1674893A CNA038198355A CN03819835A CN1674893A CN 1674893 A CN1674893 A CN 1674893A CN A038198355 A CNA038198355 A CN A038198355A CN 03819835 A CN03819835 A CN 03819835A CN 1674893 A CN1674893 A CN 1674893A
Authority
CN
China
Prior art keywords
base
oxo
bases
phenyl
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038198355A
Other languages
English (en)
Chinese (zh)
Inventor
D·多尔施
B·切赞尼
W·梅德尔斯基
C·察克拉基迪斯
J·格莱茨
C·巴恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1674893A publication Critical patent/CN1674893A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038198355A 2002-08-20 2003-07-04 苯并咪唑衍生物 Pending CN1674893A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10238002.3 2002-08-20
DE10238002A DE10238002A1 (de) 2002-08-20 2002-08-20 Benzimidazolderivate

Publications (1)

Publication Number Publication Date
CN1674893A true CN1674893A (zh) 2005-09-28

Family

ID=31197107

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038198355A Pending CN1674893A (zh) 2002-08-20 2003-07-04 苯并咪唑衍生物

Country Status (13)

Country Link
US (1) US7566789B2 (https=)
EP (1) EP1558247B1 (https=)
JP (1) JP4668614B2 (https=)
CN (1) CN1674893A (https=)
AR (1) AR041024A1 (https=)
AT (1) ATE386518T1 (https=)
AU (1) AU2003250890B2 (https=)
BR (1) BR0313634A (https=)
CA (1) CA2496139C (https=)
DE (2) DE10238002A1 (https=)
ES (1) ES2303606T3 (https=)
RU (1) RU2005108042A (https=)
WO (1) WO2004017963A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN105712937A (zh) * 2016-02-28 2016-06-29 李健 一种治疗转移性肿瘤的化合物及其用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984595B1 (ko) * 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
WO2004031145A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
BRPI0418212A (pt) * 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2008335709A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
JP2011520809A (ja) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1011190A8 (pt) 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
WO2011074658A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
PT3204381T (pt) * 2014-10-08 2022-07-18 Redx Pharma Plc Derivados de n-piridinil acetamida como inibidores da via de sinalização wnt
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2641060A1 (de) * 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CA2374947A1 (en) 1999-05-24 2000-11-30 Robert M. Scarborough Inhibitors of factor xa
DK1194425T3 (da) * 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN105712937A (zh) * 2016-02-28 2016-06-29 李健 一种治疗转移性肿瘤的化合物及其用途

Also Published As

Publication number Publication date
AR041024A1 (es) 2005-04-27
ES2303606T3 (es) 2008-08-16
JP2006500369A (ja) 2006-01-05
US7566789B2 (en) 2009-07-28
CA2496139C (en) 2011-12-13
EP1558247A1 (de) 2005-08-03
EP1558247B1 (de) 2008-02-20
CA2496139A1 (en) 2004-03-04
BR0313634A (pt) 2005-06-21
AU2003250890B2 (en) 2009-07-16
WO2004017963A1 (de) 2004-03-04
AU2003250890A1 (en) 2004-03-11
ATE386518T1 (de) 2008-03-15
JP4668614B2 (ja) 2011-04-13
US20050272740A1 (en) 2005-12-08
DE10238002A1 (de) 2004-03-04
DE50309217D1 (en) 2008-04-03
RU2005108042A (ru) 2005-11-20

Similar Documents

Publication Publication Date Title
CN1674893A (zh) 苯并咪唑衍生物
CN1481358A (zh) 酰胺衍生物和它们在治疗血栓栓塞性疾病和肿瘤中的用途
CN1518541A (zh) 苯基衍生物
CN1110305C (zh) 作为抗凝剂的萘基取代的苯并咪唑衍生物
CN1184208C (zh) 取代的苯并咪唑及其制备和用途
CN1152866C (zh) 苯并咪唑,其制法及其作为药物组合物的用途
CN1214026C (zh) 吲哚－3－基衍生物
CN1496361A (zh) 苯基衍生物3
CN1272107A (zh) 作为因子Xa抑制剂的苄脒衍生物
CN1642927A (zh) 环状酰胺
CN1305470A (zh) 脒化合物
CN101031561A (zh) 可以用作凝血因子xa抑制剂的羰基化合物
CN1390206A (zh) 因子Xa的抑制剂
CN1282329A (zh) 作为抗凝剂的邻氨基苯甲酰胺衍生物
CN1901917A (zh) 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3－氧代－3，4－二氢－喹喔啉－2－基－氨基)－苯甲酰胺衍生物和相关化合物
CN1809346A (zh) 作为凝血因子xa和viia的抑制剂用于治疗形成血栓的1－[(4－乙炔基苯基) ]－2－[(苯基)]－吡咯烷－1,2－二酰胺衍生物
CN1926137A (zh) 作为Xa因子抑制剂的吡咯衍生物
CN1418882A (zh) 取代的磺酸n－[(氨基亚氨基甲基)苯基烷基]－氮杂环酰胺化合物
CN1178915C (zh) 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
CN1886397A (zh) 作为糖原合酶激酶3(gsk3)抑制剂的3－杂环基－吲哚衍生物
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1516695A (zh) 用作抗病毒剂的芳基磺酰胺类化合物
CN1771237A (zh) 在治疗血栓栓塞性疾病中用作凝血因子 x a抑制剂的 1 － (苯基氨基甲酰基 ) － 2 － ( 4 － ( 3 －氧代－吗啉 － 4－基 ) －苯基氨基甲酰基)吡咯烷衍生物及相关化合物
CN1330638A (zh) 取代的苯并[de]异哇啉－1,3－二酮
CN1571781A (zh) 4－咪唑啉－2－酮化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083743

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083743

Country of ref document: HK